Position in NVS
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$1,813,093
+$65,022 QoQ
Shares Held
11,569
+1.1% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#457
of 1,603 holders
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Frank, Rimerman Advisors LLC holds $61,050,050 across 13 Drug Manufacturers - General names. NVS ranks #10 (3.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
11,066 | $13,272,893 | |
| 2 | JNJ |
Johnson & Johnson
|
51,668 | $13,122,121 | |
| 3 | ABBV |
AbbVie Inc.
|
34,526 | $8,688,122 | |
| 4 | MRK |
Merck & Co., Inc.
|
37,710 | $4,845,735 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
35,286 | $4,458,033 | |
| 6 | PFE |
Pfizer Inc
|
164,115 | $3,951,889 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
50,290 | $2,897,709 | |
| 8 | AMGN |
Amgen Inc
|
7,272 | $2,633,336 |
All Filings in NVS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,813,093 | 11,569 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $1,748,071 | 11,444 | Shares | Sole | 2026-04-29 | |
| 2025-12-31 | $1,553,519 | 11,268 | Shares | Sole | 2026-01-15 | |
| 2025-09-30 | $1,211,996 | 9,451 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $680,197 | 5,621 | Shares | Sole | 2025-08-11 | |
| 2025-03-31 | $302,222 | 2,711 | Shares | Sole | 2025-05-12 | |
| 2024-09-30 | $201,285 | 1,750 | Shares | Sole | 2024-10-24 | |
| 2024-06-30 | $241,877 | 2,272 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||